Amneal to Ring the Nasdaq Closing Bell on April 2, 2024

- Celebrating Amneal’s recent listing on the Nasdaq Stock Exchange

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, today announced that Chirag and Chintu Patel, Co-founders and Co-Chief Executive Officers, will ring the Nasdaq closing bell on Tuesday, April 2, 2024.

“As entrepreneurs who founded Amneal in 2002, we are pleased to join the esteemed roster of Nasdaq-listed companies. Today Amneal is a growing global pharmaceutical leader with a diverse portfolio of essential medicines that help make healthy possible. Our focus on patient access and affordability allows us to improve countless lives, and our commitment to innovation and quality enables us to create significant value for all our stakeholders. We thank the entire Amneal family for their tremendous dedication and commitment to those we serve, and we are excited for our next era of growth and success,” said Chirag and Chintu Patel.

A live stream of the event is available at: www.nasdaq.com/marketsite/bell-ringing-ceremony.

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global pharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 270 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240328005176/en/

Amneal Contact

Anthony DiMeo

Head of Investor Relations

anthony.dimeo@amneal.com

Source: Amneal Pharmaceuticals, Inc.